Skip to main content
Top
Published in: Antimicrobial Resistance & Infection Control 1/2018

Open Access 01-12-2018 | Review

Economic evaluations and their use in infection prevention and control: a narrative review

Authors: Elissa Rennert-May, John Conly, Jenine Leal, Stephanie Smith, Braden Manns

Published in: Antimicrobial Resistance & Infection Control | Issue 1/2018

Login to get access

Abstract

Background

The objective of this review is to provide a comprehensive overview of the different types of economic evaluations that can be utilized by Infection Prevention and Control practitioners with a particular focus on the use of the quality adjusted life year, and its associated challenges. We also highlight existing economic evaluations published within Infection Prevention and Control, research gaps and future directions.

Design

Narrative Review.

Conclusions

To date the majority of economic evaluations within Infection Prevention and Control are considered partial economic evaluations. Acknowledging the challenges, which include variable utilities within infection prevention and control, a lack of randomized controlled trials, and difficulty in modelling infectious diseases in general, future economic evaluation studies should strive to be consistent with published guidelines for economic evaluations. This includes the use of quality adjusted life years. Further research is required to estimate utility scores of relevance within Infection Prevention and Control.
Literature
1.
go back to reference Zoutman DE, Ford B, Bryce E, Gourdeau M, Hebert G, Henderson E, et al. The state of infection surveillance and control in Canadian acute care hospitals. Am J Infect Control. 2003;31(5):266–73.CrossRefPubMed Zoutman DE, Ford B, Bryce E, Gourdeau M, Hebert G, Henderson E, et al. The state of infection surveillance and control in Canadian acute care hospitals. Am J Infect Control. 2003;31(5):266–73.CrossRefPubMed
2.
go back to reference Stone PW, Braccia D, Larson E. Systematic review of economic analyses of health care-associated infections. Am J Infect Control. 2005;33(9):501–9.CrossRefPubMed Stone PW, Braccia D, Larson E. Systematic review of economic analyses of health care-associated infections. Am J Infect Control. 2005;33(9):501–9.CrossRefPubMed
3.
go back to reference Al-Tawfiq JA, Tambyah PA. Healthcare associated infections (HAI) perspectives. J Infect Public Health. 2014;7(4):339–44.CrossRefPubMed Al-Tawfiq JA, Tambyah PA. Healthcare associated infections (HAI) perspectives. J Infect Public Health. 2014;7(4):339–44.CrossRefPubMed
4.
go back to reference Storr J, Twyman A, Zingg W, Damani N, Kilpatrick C, Reilly J, et al. Core components for effective infection prevention and control programmes: new WHO evidence-based recommendations. Antimicrob Resist Infect Control. 2017;6(5):6.CrossRefPubMedPubMedCentral Storr J, Twyman A, Zingg W, Damani N, Kilpatrick C, Reilly J, et al. Core components for effective infection prevention and control programmes: new WHO evidence-based recommendations. Antimicrob Resist Infect Control. 2017;6(5):6.CrossRefPubMedPubMedCentral
5.
go back to reference Scheckler WE, Brimhall D, Buck AS, Farr B, Friedman C, Garibaldi R, et al. Requirements for infrastructure and essential activities of infection control and epidemiology in hospitals: a consensus panel report. Society for Healthcare Epidemiology of America. Infect Control Hosp Epidemiol. 1998;19(2):114–24.CrossRefPubMed Scheckler WE, Brimhall D, Buck AS, Farr B, Friedman C, Garibaldi R, et al. Requirements for infrastructure and essential activities of infection control and epidemiology in hospitals: a consensus panel report. Society for Healthcare Epidemiology of America. Infect Control Hosp Epidemiol. 1998;19(2):114–24.CrossRefPubMed
6.
go back to reference Bryant KA, Harris AD, Gould CV, Humphreys E, Lundstrom T, Murphy D, et al. Necessary infrastructure of infection prevention and healthcare epidemiology programs: a review. Infect Control Hosp Epidemiol. 2016;37(4):371–80.CrossRefPubMedPubMedCentral Bryant KA, Harris AD, Gould CV, Humphreys E, Lundstrom T, Murphy D, et al. Necessary infrastructure of infection prevention and healthcare epidemiology programs: a review. Infect Control Hosp Epidemiol. 2016;37(4):371–80.CrossRefPubMedPubMedCentral
7.
go back to reference Graves N, Harbarth S, Beyersmann J, Barnett A, Halton K, Cooper B. Estimating the cost of health care-associated infections: mind your p's and q's. Clin Infect Dis. 2010;50(7):1017–21.CrossRefPubMed Graves N, Harbarth S, Beyersmann J, Barnett A, Halton K, Cooper B. Estimating the cost of health care-associated infections: mind your p's and q's. Clin Infect Dis. 2010;50(7):1017–21.CrossRefPubMed
8.
go back to reference Drummond MF, Davies LM. Evaluation of the costs and benefits of reducing hospital infection. J Hosp Infect. 1991;18(Supplement A):85–93.CrossRefPubMed Drummond MF, Davies LM. Evaluation of the costs and benefits of reducing hospital infection. J Hosp Infect. 1991;18(Supplement A):85–93.CrossRefPubMed
9.
go back to reference Whittington MD, Atherly AJ, Curtis DJ, Lindrooth RC, Bradley CJ, Campbell JD. Recommendations for methicillin-resistant Staphylococcus aureus prevention in adult ICUs: a cost-effectiveness analysis. Crit Care Med. 2017;45(8):1304–10.CrossRefPubMed Whittington MD, Atherly AJ, Curtis DJ, Lindrooth RC, Bradley CJ, Campbell JD. Recommendations for methicillin-resistant Staphylococcus aureus prevention in adult ICUs: a cost-effectiveness analysis. Crit Care Med. 2017;45(8):1304–10.CrossRefPubMed
10.
go back to reference Li CK, Tong BCY, You JHS. Cost-effectiveness of culture-guided antimicrobial prophylaxis for the prevention of infections after prostate biopsy. Int J Infect Dis. 2016;43:7–12.CrossRefPubMed Li CK, Tong BCY, You JHS. Cost-effectiveness of culture-guided antimicrobial prophylaxis for the prevention of infections after prostate biopsy. Int J Infect Dis. 2016;43:7–12.CrossRefPubMed
11.
go back to reference Hayman DTS, Marshall JC, French NP, Carpenter TE, Roberts MG, Kiedrzynski T. Cost benefit analyses of supplementary measles immunisation in the highly immunized population of New Zealand. Vaccine. 2017;35(37):4913–22.CrossRefPubMed Hayman DTS, Marshall JC, French NP, Carpenter TE, Roberts MG, Kiedrzynski T. Cost benefit analyses of supplementary measles immunisation in the highly immunized population of New Zealand. Vaccine. 2017;35(37):4913–22.CrossRefPubMed
13.
go back to reference Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated health economic evaluation reporting standards (CHEERS)--explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force. Value Health. 2013;16(2):231–50.CrossRefPubMed Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated health economic evaluation reporting standards (CHEERS)--explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force. Value Health. 2013;16(2):231–50.CrossRefPubMed
14.
15.
go back to reference Drummond MF, Sculpher M, Claxton K, Stoddart G, Torrance G. Methods for the economic evaluation of health care programmes. Fourth ed. New York: Oxford University Press; 2015. Drummond MF, Sculpher M, Claxton K, Stoddart G, Torrance G. Methods for the economic evaluation of health care programmes. Fourth ed. New York: Oxford University Press; 2015.
16.
go back to reference Graves N, Halton LD. Economics and preventing hospital-acquired infection: broadening the perspective. Infect Control Hosp Epidemiol. 2007;28(2):178–84.CrossRefPubMed Graves N, Halton LD. Economics and preventing hospital-acquired infection: broadening the perspective. Infect Control Hosp Epidemiol. 2007;28(2):178–84.CrossRefPubMed
17.
go back to reference Raschka S, Dempster L, Bryce E. Health economic evaluation of an infection prevention and control program: are quality and patient safety programs worth the investment? Am J Infect Control. 2013;41(9):773–7.CrossRefPubMed Raschka S, Dempster L, Bryce E. Health economic evaluation of an infection prevention and control program: are quality and patient safety programs worth the investment? Am J Infect Control. 2013;41(9):773–7.CrossRefPubMed
18.
go back to reference Leonhardt KK, Yakusheva O, Phelan D, Reeths A, Hosterman T, Bonin D, et al. Clinical effectiveness and cost benefit of universal versus targeted methicillin-resistant Staphylococcus aureus screening upon admission in hospitals. Infect Control Hosp Epidemiol. 2011;32(8):797–803.CrossRefPubMed Leonhardt KK, Yakusheva O, Phelan D, Reeths A, Hosterman T, Bonin D, et al. Clinical effectiveness and cost benefit of universal versus targeted methicillin-resistant Staphylococcus aureus screening upon admission in hospitals. Infect Control Hosp Epidemiol. 2011;32(8):797–803.CrossRefPubMed
19.
go back to reference Stone PW, Larson E, Kawar LN. A systematic audit of economic evidence linking nosocomial infections and infection control interventions: 1990-2000. Am J Infect Control. 2002;30(3):145–52.CrossRefPubMed Stone PW, Larson E, Kawar LN. A systematic audit of economic evidence linking nosocomial infections and infection control interventions: 1990-2000. Am J Infect Control. 2002;30(3):145–52.CrossRefPubMed
20.
go back to reference Arefian H, Vogel M, Kwetkat A, Hartmann M. Economic evaluation of interventions for prevention of hospital acquired infections: a systematic review. PLoS One. 2016;11(1):e0146381.CrossRefPubMedPubMedCentral Arefian H, Vogel M, Kwetkat A, Hartmann M. Economic evaluation of interventions for prevention of hospital acquired infections: a systematic review. PLoS One. 2016;11(1):e0146381.CrossRefPubMedPubMedCentral
21.
go back to reference Roberts RR, Ek M, Weinstein RA. A guide to interpreting economic studies in infectious diseases. Clin Microbiol Infect. 2010;16(12):1713–20.CrossRefPubMed Roberts RR, Ek M, Weinstein RA. A guide to interpreting economic studies in infectious diseases. Clin Microbiol Infect. 2010;16(12):1713–20.CrossRefPubMed
22.
go back to reference Dick A, Perencevich EN, Pogorzelska-Maziarz M, Zwanziger J, Larson EL, Stone PW. A decade of investment in infection prevention: a cost effectiveness analysis. Am J Infect Control. 2015;43(1):4–9.CrossRefPubMedPubMedCentral Dick A, Perencevich EN, Pogorzelska-Maziarz M, Zwanziger J, Larson EL, Stone PW. A decade of investment in infection prevention: a cost effectiveness analysis. Am J Infect Control. 2015;43(1):4–9.CrossRefPubMedPubMedCentral
23.
go back to reference Stone PW, Schackman BR, Neukermans CP, Olchanski N, Greenberg D, Rosen A, et al. A synthesis of cost-utility analysis literature in infectious disease. Lancet Infect Dis. 2005;5(6):383–91.CrossRefPubMed Stone PW, Schackman BR, Neukermans CP, Olchanski N, Greenberg D, Rosen A, et al. A synthesis of cost-utility analysis literature in infectious disease. Lancet Infect Dis. 2005;5(6):383–91.CrossRefPubMed
24.
go back to reference Pettitt DA, Raza S, Naughton B, Roscoe A, Ramakrishnan A, Ali A, et al. The limitations of QALY: a literature review. J Stem Cell Res Ther. 2016;6:334–6. Pettitt DA, Raza S, Naughton B, Roscoe A, Ramakrishnan A, Ali A, et al. The limitations of QALY: a literature review. J Stem Cell Res Ther. 2016;6:334–6.
25.
go back to reference Knapp M, Mangalore R. The trouble with QALYs.... Epidemiol Psychiatr Soc. 2007;16(4):289–93.CrossRef Knapp M, Mangalore R. The trouble with QALYs.... Epidemiol Psychiatr Soc. 2007;16(4):289–93.CrossRef
26.
go back to reference Ogwulu CB, Jackson LJ, Kinghorn P, Roberts TE. A systematic review of the techniques used to value temporary health states. Value Health. 2017;20(8):1180–97.CrossRefPubMed Ogwulu CB, Jackson LJ, Kinghorn P, Roberts TE. A systematic review of the techniques used to value temporary health states. Value Health. 2017;20(8):1180–97.CrossRefPubMed
27.
go back to reference Cunningham SJ. Economic evaluation of healthcare-is it important to us? Br Dent J. 2000;188(5):250–4.CrossRefPubMed Cunningham SJ. Economic evaluation of healthcare-is it important to us? Br Dent J. 2000;188(5):250–4.CrossRefPubMed
28.
go back to reference Gu N, Wolf C, Leopold S, Manner PA, Doctor JN. A comparison of physician and patient time trade-offs for postoperative hip outcomes. Value Health. 2009;12(4):618–20.CrossRefPubMed Gu N, Wolf C, Leopold S, Manner PA, Doctor JN. A comparison of physician and patient time trade-offs for postoperative hip outcomes. Value Health. 2009;12(4):618–20.CrossRefPubMed
Metadata
Title
Economic evaluations and their use in infection prevention and control: a narrative review
Authors
Elissa Rennert-May
John Conly
Jenine Leal
Stephanie Smith
Braden Manns
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Antimicrobial Resistance & Infection Control / Issue 1/2018
Electronic ISSN: 2047-2994
DOI
https://doi.org/10.1186/s13756-018-0327-z

Other articles of this Issue 1/2018

Antimicrobial Resistance & Infection Control 1/2018 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.